Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 2, 2016, Pages 178-185

  Costabel, Ulrich ^a   Inoue, Yoshikazu ^b   Richeldi, Luca ^c   Collard, Harold R ^d   Tschoepe, Inga ^e   Stowasser, Susanne ^f   Azuma, Arata ^g  

^a RUHRLANDKLINIK   (Germany)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BOEHRINGER INGELHEIM   (France)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Disease progression; Forced vital capacity; Quality of life

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; NINTEDANIB; ENZYME INHIBITOR; INDOLE DERIVATIVE;

AGED; ARTICLE; DRUG EFFICACY; DRUG USE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY;

DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; VITAL CAPACITY;

EID: 84975801947     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201503-0562OC     Document Type: Article

References (24)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183: 431-440.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370: 2083-2092.
4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-2082.
5. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-4782.
6. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349: 209-220.
7. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, Sun Q, Mandal J, Lardinois D, Lambers C, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 2014;15:157.
8. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-1445.
9. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-1087.
10. Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, et al. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 2014;108:1023-1030.
11. Costabel U, Inoue Y, Richeldi L, Collard HR, Stowasser S, Tschoepe I, Azuma A. Effect of baseline FVC on decline in lung function with nintedanib: results from the INPULSIS trials [abstract]. Eur Respir J 2014;44:A1907.
12. Costabel U, Richeldi L, Azuma A, Inoue Y, Collard HR, Tschoepe I, Stowasser S, Selman M. Pre-specified subgroup analyses of pooled data from the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Presented at the International Colloquium on Lung and Airway Fibrosis (ICLAF). September 20-24, 2014, Mont Tremblant, Quebec, Canada.
13. Taniguchi H, Xu Z, Azuma A, Inoue Y, Li H, Fujimoto T, Bailes Z, Schlenker-Herceg R, Kim DS. Subgroup analysis of Asian patients in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis [abstract]. Respirology 2014;19(Suppl 3):1-62, Abstract O-I-007.
14. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Draft guideline on the investigation of subgroups in confirmatory clinical trials. 2014 [accessed 2015 Sept 1]. Available from: http://www.ema.europa.eu/ema/doc-index.jsp?curl=pages/includes/document/document-detail.jsp?webContentId=WC500160523&murl=menus/document-library/document-library.jsp&mid=0b01ac058009a3dc
15. Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, et al; Pirfenidone Clinical Study Group in Japan. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143.
16. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV (nintedanib) prescribing information. 2014. [accessed 2015 Jan 16]. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing1Information/PIs/Ofev/ofev.pdf
17. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet Investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013;14:73.
18. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356-363.
19. Han MK, Swigris J, Liu L, Bartholmai B, Murray S, Giardino N, Thompson B, Frederick M, Li D, Schwarz M, et al. Gender influences health-related quality of life in IPF. Respir Med 2010;104:724-730.
20. Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes 2014;12:124.
21. Cottin V, Taniguchi H, Richeldi L, Collard HR, Kaye M, Hansell DM, Bailes Z, Schlenker-Herceg R, Raghu G. Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS trials. Presented at the International Colloquium on Lung and Airway Fibrosis (ICLAF). September 20-24, 2014, Mont Tremblant, Quebec, Canada.
22. Kolb M, Richeldi L, Kimura T, Stowasser S, Hallmann C, du Bois RM. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS trials [abstract]. Am J Respir Crit Care Med 2015;191:A1021.
23. Raghu G, Wells A, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM. Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS trials in IPF [abstract]. Am J Respir Crit Care Med 2015;191:A1022.
24. Boehringer Ingelheim. OFEV (nintedanib). Summary of product characteristics. 2015 [accessed 2015 Jun 1]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003821/WC500182474.pdf